Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic ...

Illumina, Inc. ILMN launched the TruSight Oncology (“TSO”) Comprehensive (EU)— a single test that evaluates multiple tumor genes and biomarkers to identify the specific molecular profile of a ...

BOSTON, May 30, 2025 /PRNewswire/ -- Velsera announces that its clinical Knowledgebase is powering the interpretation framework behind Illumina's TruSight™ Oncology Comprehensive (TSO Comp) assay, ...